Repros Therapeutics Needs New Pivotal Trial For Low T Drug Enclomiphene
This article was originally published in The Pink Sheet Daily
Complete response letter from FDA follows abrupt cancellation of advisory committee meeting.
You may also be interested in...
Draft is intended to inform development of non-testosterone products such as aromatase inhibitors or estrogen receptor agonists.
Baxter, Ariad, Diurnal. Kyowa Kirin and AB Science are among the companies that will likely shortly find out what remaining concerns the European Medicines Agency’s key advisory panel, the CHMP, has regarding products of theirs that are under review.
US agency's decision not to hold a February advisory committee review of tardive dyskinesia treatment viewed positively by Neurocrine, which emphasized quality of its communications with the review division and the drug's breakthrough therapy status.